150 likes | 357 Views
Background. iPrEx trial demonstrated 44% reduction in HIV acquisition with FTC/TDF PrEP in MSMRisk practices decreased in both FTC/TDF and placebo arm; participants provided a comprehensive package of prevention servicesSimilar decreases in risk behaviors seen among MSM in the US CDC safety study
E N D
1. Risha Irvin, MD/MPH
San Francisco dept. of public health
Prevention umbrella for msm in the americas (PUMA) Risk Compensation and Pre-Exposure Prophylaxis (PrEP): A Post-iPrEx Survey of US Men who have Sex with Men (MSM)
2. Background iPrEx trial demonstrated 44% reduction in HIV acquisitionwith FTC/TDF PrEP in MSM
Risk practices decreased in both FTC/TDF and placebo arm; participants provided a comprehensive package of prevention services
Similar decreases in risk behaviors seen among MSM in the US CDC safety study (Liu-Poster #MOPE381)
However, with known PrEP efficacy, sexual practices may change among individuals using PrEP
Previous surveys suggest potential for risk compensation1 which could undermine benefits2
iPrEx Open Label Extension and planned demonstration projects will evaluate sexual practices among MSM taking open-label PrEP
We conducted an internet survey of MSM to evaluate potential for changes in sexual behaviors with PrEP and identify factors associated with PrEP uptake
3. Online survey -- methods Participants recruited from social networking sites (Facebook, Black Gay Chat)
Facebook: men interested in men, and US state
Black Gay Chat: All users
Banner ads used to recruit men to a screener and informed consent process
Analysis restricted to those who reported sex with men, were not HIV-infected, and completed questions about risk perception
4. Online survey – Methods, cont. Data collected from November 30 – Dec 19, 2010
Administered through a secure, online survey provider (SurveyGizmo)
Of 2,701 men initiating the survey by providing demographic information, 1,155 (43%) provided all required data for this analysis
5. Methods, continued Topic areas include:
Knowledge and willingness to use PrEP
Perception of HIV risk from unprotected insertive (UIAI) and receptive (URAI) anal intercourse with/out PrEP (known efficacy)
Perception of pleasure from sex with/out PrEP
Perception of likelihood to feel pressure to have sex without a condom with/out PrEP
We used multivariate logistic regression to evaluate factors associated with willingness to use PrEP
6. Participant characteristics (n=1,155)
7. Data-PrEP knowledge and intent to use PrEP
8. If you had anal sex as a TOP/BOTTOM without a condom, to what extent do you believe that you would be at risk of getting HIV? Perceived risk of UAI
9. Data-Risk Compensation
10. If you had anal sex as a BOTTOM without a condom, to what extent would it provide you with pleasure or other benefits?
To what extent do you feel pressure from other people to have UAI? Pleasure from and pressure to have unprotected anal sex
11. Intent to use PrEP
12. Factors associated with intent to use PrEPMultivariate Model
13. Summary Almost half of participants reported that they were very/extremely likely to use PrEP
While most participants believed that PrEP offered no change or decreased risk of HIV from UAI, most did not anticipate that PrEP would change their risk practices concerning condom use; a small minority did anticipate less condom use which would offset benefit
About 1/3 felt PrEP may increase pressure from others to have unprotected anal sex
Belief that PrEP reduces HIV risk of URAI, higher levels of pleasure with URAI, and feeling pressured to have unprotected anal sex were associated with willingness to use PrEP
14. Conclusions PrEP offers much promise as the first biomedical intervention to have success in at-risk MSM
Providing education and accurate messaging around PrEP may help increase uptake and reduce risk compensation—these strategies can be evaluated in future demonstration projects
15. Acknowledgements San Francisco Department of Public Health
PUMA
Prepare SF Team
Susan Buchbinder, Albert Liu, Liz Kroboth, Eric Vittinghoff, Russ Tarver, Patrick Sullivan, Sarit Golub, Beryl Koblin (co-authors)
HIV Prevention Trials Network (Scholar)